文献速递临床试验与 GCP流行病学与生物统计

叶黄素补充对中心性肥胖成人炎症标志物与代谢危险因素影响的随机对照研究方案

Effects of lutein supplementation on inflammatory biomarkers and metabolic risk factors in adults with central obesity: study protocol for a randomised controlled study.
PubMed 文献 · Trials · 2020-01-06

本研究为双盲、平行、安慰剂对照临床试验方案,拟纳入120名18至60岁中心性肥胖成人,按1:1随机分为干预组与安慰剂组,干预组每日补充10 mg叶黄素,持续12周。研究将评估叶黄素对血清叶黄素、血糖血脂谱、炎症因子及体成分的影响,并采用意向性治疗与符合方案两个人群分析。

要点

  • 每日10 mg叶黄素补充12周,观察对中心性肥胖成人炎症因子与代谢指标的影响
  • 采用双盲、平行、安慰剂对照设计,按性别、年龄和腰围1:1随机分组
  • 研究结果可能为中心性肥胖相关炎症疾病的预防提供依据

核心结论

  • 该方案拟验证叶黄素补充对中心性肥胖成人炎症生物标志物与代谢危险因素的效应,结果尚待试验完成。

研究设计与样本

  • 双盲、平行、安慰剂对照随机对照试验方案,计划纳入120名18至60岁中心性肥胖成人,按性别、年龄和腰围以1:1比例随机分组。
  • 干预组每日补充10 mg叶黄素,持续12周;数据分析采用意向性治疗人群与符合方案人群两种策略。

主要发现

  • 原文为研究方案,尚未报告试验结果。

关键数值与推荐

  • 干预剂量为每日10 mg叶黄素,干预时长12周,样本量120人,随机比例1:1。
  • 纳入标准包括中心性肥胖、年龄18至60岁并愿意签署知情同意书。

临床怎么用

  • 该方案尚处于实施阶段,暂不能据此形成临床推荐;完成后可为中心性肥胖人群炎症相关疾病的预防提供参考。

局限性

  • 原文未报告试验结果,方案阶段尚不能确认叶黄素的疗效与安全性;研究结论有待试验完成后获得。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of central obesity is constantly increasing, and visceral fat is associated with increased production of inflammatory factors and metabolic risk factors. Lutein might retard the development of metabolic disease through its antioxidant and anti-inflammatory properties. Furthermore, epidemiological studies have associated higher dietary intake and serum levels of lutein with decreased adiposity. However, few randomised controlled trials have shown the effects of lutein supplementation on inflammatory biomarkers and metabolic risk factors, especially in adults with central obesity. METHODS: This study will be conducted as a double-blind, parallel placebo-controlled clinical trial in which 120 people who have central obesity, are 18 to 60 years old and are willing to provide informed consent will be randomly assigned to the intervention or placebo group in a 1:1 ratio according to sex, age and waist circumference. The intervention group will receive 10 mg daily lutein supplementation for 12 weeks to explore the effect of lutein supplementation on serum lutein, glycaemic and lipid profiles, inflammatory factors and body composition. Two populations (intention-to-treat population and per-protocol population) will be used in the data analyses. DISCUSSION: Our findings from this trial will contribute to the knowledge of the association between lutein supplementation and inflammatory biomarkers and metabolic risk factors in people with central obesity and will offer a possibility for the prevention of inflammatory diseases. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR1800018098. Registered on 30 August 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhou J, Zhao D, Wang N, et al. Effects of lutein supplementation on inflammatory biomarkers and metabolic risk factors in adults with central obesity: study protocol for a randomised controlled study. Trials. 2020. PMID: 31907080. doi:10.1186/s13063-019-3998-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。